Overview
Male accessory gland infections (MAGI) encompass inflammatory conditions affecting the male reproductive accessory glands, including the prostate, seminal vesicles, and epididymis. These infections can significantly impact male fertility and reproductive health. The pathophysiology of MAGI involves complex interactions between inflammatory mediators, oxidative stress, and metabolic factors, leading to impaired semen quality and potential long-term complications. The prevalence of MAGI varies widely, ranging from 2% to 18%, largely due to differences in diagnostic criteria and clinical assessment methods [PMID:35268056]. Clinically, MAGI manifests through a spectrum of symptoms and semen abnormalities, necessitating a multifaceted diagnostic and therapeutic approach.
Pathophysiology
MAGI disrupts male fertility through multiple mechanisms, primarily affecting seminal plasma composition, causing tract obstructions, and inducing sperm damage via inflammatory mediators and reactive oxygen species (ROS). Elevated ROS levels lead to a redox imbalance, compromising sperm function and integrity [PMID:41828712]. This oxidative stress can result in mitochondrial dysfunction, increased apoptosis, and higher sperm chromatin fragmentation, all of which correlate strongly with poorer reproductive outcomes [PMID:41828712]. Metabolic factors, particularly obesity, exacerbate the risk of prostate inflammation, highlighting the interconnectedness between metabolic health and the incidence of MAGI [PMID:35268056]. Research indicates that higher white blood cell counts in MAGI contribute to further degradation of sperm quality through enhanced ROS production and the effects of cytokines such as IL-1 alpha, IL-1 receptor antagonist (IL-1 RA), and IL-8 [PMID:9016401]. These cytokines not only promote inflammation but also directly impact sperm parameters, underscoring the importance of systemic inflammation in the pathophysiology of MAGI.
Epidemiology
The incidence of male accessory gland infections/inflammations (MAGI) exhibits considerable variability, with reported frequencies ranging from 2% to 18% [PMID:35268056]. This wide range is attributed to variations in diagnostic criteria, clinical assessment methods, and the inclusion of different patient populations. Factors such as age, lifestyle, and underlying health conditions, including metabolic disorders like obesity, influence susceptibility to MAGI [PMID:35268056]. Epidemiological studies suggest that certain populations, such as those with compromised immune systems or those engaging in high-risk sexual behaviors, may have higher incidences of MAGI. Understanding these epidemiological nuances is crucial for targeted screening and prevention strategies in clinical practice.
Clinical Presentation
Clinically, MAGI often presents with a constellation of symptoms that extend beyond mere reproductive dysfunction. Impaired semen parameters, including reduced sperm motility, concentration, and morphology, are hallmark findings [PMID:41828712]. Biofunctional alterations in sperm, such as decreased mitochondrial membrane potential, increased apoptosis, and elevated sperm chromatin fragmentation, are frequently observed and correlate directly with poorer reproductive outcomes [PMID:41828712]. Patients frequently report a range of symptoms including urinary symptoms like dysuria and frequency, pelvic pain, and sexual dysfunction, which can significantly impact quality of life [PMID:35268056]. These symptoms can be systematically assessed using validated questionnaires that target functional domains such as urinary symptoms, pain, and sexual health [PMID:35268056]. Notably, even in the absence of overt white blood cells in semen, elevated levels of cytokines like hepatocyte growth factor (HGF), IL-8, and IL-6 can correlate with alterations in sperm concentration and enzyme activities, providing additional biomarkers for assessing reproductive function [PMID:9016401].
Diagnosis
Diagnosing MAGI involves a combination of clinical assessment, laboratory tests, and biomarker evaluation. Semen analysis remains a cornerstone diagnostic tool, revealing abnormalities such as increased white blood cells, altered sperm morphology, and reduced motility [PMID:9016401]. Among the various biomarkers, IL-6 in seminal plasma stands out as a highly specific and sensitive marker for diagnosing MAGI, effectively distinguishing affected individuals from those without the condition [PMID:9016401]. Additionally, elevated levels of other inflammatory cytokines, such as IL-8 and IL-1 alpha, can support the diagnosis by reflecting ongoing inflammation within the reproductive tract [PMID:9016401]. In clinical practice, a comprehensive approach that integrates clinical symptoms, semen analysis, and biomarker assessment provides a robust framework for accurate diagnosis and subsequent management planning.
Management
The management of MAGI typically follows a sequential therapeutic approach tailored to the severity and specific manifestations of the condition. Antibiotic therapy is often initiated as the first line of treatment, targeting common pathogens such as Escherichia coli and Staphylococcus epidermidis [PMID:35268056]. However, in cases where antibiotic efficacy is limited or recurrent infections occur, alternative strategies are considered. Nutraceuticals with anti-inflammatory and antioxidant properties, such as Deprox-HP, have shown promise in mitigating inflammation and oxidative stress, potentially improving outcomes in refractory cases [PMID:41828712]. Dietary interventions, particularly very low carbohydrate ketogenic diets (VLCKD), characterized by reduced carbohydrate intake and increased fat and protein consumption, have demonstrated potential benefits in managing symptoms like voiding disorders and sexual/ejaculatory discomfort, particularly in conditions like inflammatory bilateral prostate vesicular epididymitis (PVE) [PMID:35268056]. Following antibiotic therapy, anti-inflammatory agents or corticosteroids may be employed to control persistent inflammation [PMID:35268056]. Antioxidant therapy can further address oxidative stress, while α-blockers and phosphodiesterase type 5 inhibitors are utilized to alleviate specific symptoms such as urinary obstruction and erectile dysfunction, respectively [PMID:35268056]. Comprehensive follow-up and monitoring are essential to adjust treatment as needed and ensure sustained improvement in reproductive health.
Complications
MAGI can lead to several significant complications that further compromise male fertility and overall reproductive health. Elevated levels of ROS and inflammatory cytokines contribute to lipid peroxidation, a process that damages sperm membranes, impairs sperm motility, and reduces fertilization potential [PMID:41828712]. Chronic inflammation can also result in persistent alterations in seminal fluid composition, exacerbating issues like sperm DNA damage and increased sperm DNA fragmentation [PMID:41828712]. These complications not only affect immediate fertility but also increase the risk of recurrent pregnancy loss and long-term reproductive health issues, underscoring the importance of timely and effective management of MAGI.
Prognosis & Follow-up
The prognosis for patients with MAGI varies based on the severity of the condition, response to treatment, and underlying health factors. Elevated levels of sperm chromatin fragmentation are particularly concerning, as they are strongly associated with an increased risk of recurrent pregnancy loss and poorer reproductive outcomes [PMID:41828712]. Regular follow-up is crucial for monitoring these biomarkers and assessing the effectiveness of therapeutic interventions. Clinicians should routinely evaluate semen parameters, including sperm chromatin integrity, to guide adjustments in treatment strategies and to provide prognostic insights to patients. Long-term monitoring helps in identifying patients at higher risk for complications and in implementing preventive measures to mitigate adverse reproductive outcomes.
References
1 Di Nicuolo F, Oliva A, Vodola EP, Cicchinelli M, Iavarone F, Di Nardo C et al.. Seminal Redox Improvement and Sperm Proteome Remodeling After Deprox-HP Nutraceutical Supplementation in Male Accessory Gland Inflammation: A Pilot Study. International journal of molecular sciences 2026. link 2 Condorelli RA, Aversa A, Basile L, Cannarella R, Mongioì LM, Cimino L et al.. Beneficial Effects of the Very-Low-Calorie Ketogenic Diet on the Symptoms of Male Accessory Gland Inflammation. Nutrients 2022. link 3 Depuydt CE, Bosmans E, Zalata A, Schoonjans F, Comhaire FH. The relation between reactive oxygen species and cytokines in andrological patients with or without male accessory gland infection. Journal of andrology 1996. link